Natera, Inc. business relationships
Companies named in Natera, Inc.’s 10-K filed 2026-02-27, and public companies whose annual reports name Natera, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 6.1 / 10
- AI naming
- 100 / 100 Top 1% in its category
- Agent readiness
- 35 / 100
- AI adoption
- 0 / 100
Named in Natera, Inc.’s annual report 6
“...event of any technical problems that may arise in connection with our on‑site data center, the DNAnexus platform or the AWS servers on which the DNAnexus platform is hosted, or the AWS servers that host our data directly, or difficulties in or termination of our relationship with DNAnexus, we could...” SEC filing
“We host the majority of these algorithms on a cloud‑based software platform pursuant to an agreement with DNAnexus, Inc., or DNAnexus, and both we and our Constellation licensees access our algorithms through the DNAnexus platform.” SEC filing
“The DNAnexus platform is hosted on third‑party data center hosting facilities operated by Amazon Web Services, or AWS, located primarily in the United States and in the European Union.” SEC filing
“The Company also recognizes revenues from its strategic collaboration agreements, such as those with BGI Genomics Co., Ltd. ("BGI Genomics") and Foundation Medicine, Inc. ("Foundation Medicine").” SEC filing
“We are aware that Illumina has required our licensees, in order to secure a supply agreement for the sequencers and reagents necessary to run NIPT under our cloud-based distribution model, to pay an additional fee for a license under the pooled intellectual property in jurisdictions in which Illumin...” SEC filing
“Furthermore, our sequencers, sourced from Illumina, as well as certain other reagents we use for Panorama and our other tests, are intended for research use only and are labeled as RUO.” SEC filing
Companies whose annual reports name Natera, Inc. 6
“• In January 2026, we announced a collaboration with Natera, on STELLAR-316, a planned phase 3 pivotal trial, which we anticipate will commence in mid-2026.” SEC filing
“The jury awarded Natera approximately $ 96.3 million in damages based on sales of AlloSure and AlloSeq between September 2021 and August 2023.” SEC filing
“On June 4, 2026, Natera, Inc. and CytoDyn jointly announced a strategic collaboration to advance ctDNA-guided development and molecular response analysis in metastatic colorectal cancer.” SEC filing
“Natera accounted for 8% and 30% of our revenue for the years ended December 31, 2025 and 2024, respectively.” SEC filing
“Revenue from our partnership with Natera to provide advanced tumor analysis for use in Natera's MRD test currently makes up substantially all of the revenue in this category.” SEC filing
“We are also aware of at least one third party supplier of DNA sequencing and analysis services, such that Natera has elected, and may continue to elect in the future, to send a portion (or all) of its samples to its other supplier(s) instead of us, which it is not contractually prohibited from doing...” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.